Could a diabetes drug tame asthma in obesity? new trial investigates

NCT ID NCT05254314

Ongoing Disease control Sponsor: Vanderbilt University Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests whether semaglutide (Wegovy), a drug approved for diabetes and weight loss, can improve asthma control in 100 adults with obesity and persistent asthma despite using inhaled steroids. Participants receive weekly injections of semaglutide or a placebo for up to 24 weeks. The study measures changes in asthma symptoms and airway inflammation to see if the drug has direct benefits beyond weight loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Semaglutide (Wegovy) injection
What this could lead to: If it works, this could point toward a new treatment option for people with obesity-related asthma that is not well controlled with standard inhalers.
What could go wrong: This is a mid-stage trial with only 100 participants, so results may not apply to everyone. Semaglutide can cause side effects like nausea and vomiting, and it is not yet proven to help asthma directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma Obesity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA

Contacts and locations

Locations

Vanderbilt University Medical Center

Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.